Drug Repositioning and the 505(b)(2) Application: A Step-by-Step Approach to a Fuller, More Profitable Pipeline

Listen closely while Kenneth Phelps, president and CEO of Camargo Pharmaceutical Services, compares the various new drug approval applications and shows you when a 505(b)(2) is the best choice.


Audio CD/Transcript - Dec. 12, 2007 The Audio CD/Transcript will be shipped the week of Jan. 7, 2008.